Glycotope Biotechnology
- Company typePrivate
- Founded2001
- HeadquartersHeidelberg, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
Glycotope Biotechnology firmographics
Firmographics- Name
- Glycotope Biotechnology
- Legal name
- e-pixler NEW MEDIA GmbH
- Website
- https://glycotope.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Glycotope Biotechnology industry classification
Industry- Product category
- Biopharmaceutical R&D
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Glycotope Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Markets served
Glycotope Biotechnology business model
Business model- GTM type
- B2B
- Offering type
- Services
Glycotope Biotechnology product offering
Product offeringCore offering
Glycotope Biotechnology is described as a Drug Development and BioEngineering company, indicating it conducts biopharmaceutical research and development activities. The firmographics place it in the biotechnology sector with operations based in Heidelberg, Germany. The provided input does not include product-specific, technology-specific, or pipeline-specific details.
Differentiator
Problem solved
Functional benefit
Glycotope Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Glycotope Biotechnology partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
Glycotope Biotechnology competitors and assessment
Company assessmentBroad incumbents
- Roche: Roche is a global biopharmaceutical leader with one of the largest biologics pipelines — broadly comparable as a backdrop incumbent for glyco-engineered/biological therapeutics commercialization and as a likely partner/acquirer for Glycotope-type assets.
- Merck KGaA: Merck KGaA is a German-headquartered science and technology company with significant biopharma and life-science tools activity (including Sigma-Aldrich), providing a relevant regional incumbent comparand for both therapeutics and bioengineering services.
Emerging players
- AbCellera Biologics: AbCellera is a Canadian antibody discovery and development company leveraging a high-throughput single-cell platform — relevant as an emerging technology-driven biologics developer with comparable platform-leveraging model.
Regional players
- Evotec: Evotec is a Germany-headquartered drug discovery and development services company with a strong biologics/protein engineering offering, providing a relevant regional comparand for platform-enabled biologics development.
Direct peers
- MacroGenics: MacroGenics is a US clinical-stage biotech developing engineered antibody-based therapeutics, including ADCs and bispecifics — closely comparable in the bioengineered biologics drug development niche that Glycotope occupies.
- argenx: argenx is a Belgium-based biotech focused on engineered antibody therapeutics with a strong immunology pipeline, providing a clear comparand for Glycotope's biologics development approach and target product profile strategy.
- Genmab: Genmab is a Denmark-based biotech developing differentiated antibody therapeutics, with proprietary technology platforms for engineering antibodies — directly comparable to Glycotope's bioengineering-led, antibody-based drug development model.
- BioInvent International: BioInvent is a Sweden-based clinical-stage biotech developing tumor-directed antibody therapeutics using proprietary technology platforms — comparable in stage, modality, and platform-based drug development approach.
- MorphoSys: MorphoSys is a German antibody-discovery and development biotech historically based near Munich — directly comparable in geography and in focus on antibody therapeutics, with overlapping technology and pipeline profiles to Glycotope.
Others
- Lonza Group: Lonza is a Swiss-headquartered global CDMO with deep biologics manufacturing capabilities — adjacent comparand relevant to Glycotope's CMC/bioprocessing requirements and potential manufacturing partner ecosystem.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
Glycotope Biotechnology social profiles
Digital presenceGlycotope Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Glycotope Biotechnology leadership team
Management profileNumber of profiles
Glycotope Biotechnology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Glycotope Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Glycotope Biotechnology
What does Glycotope Biotechnology do?
Glycotope Biotechnology is described as a Drug Development and BioEngineering company, indicating it conducts biopharmaceutical research and development activities. The firmographics place it in the biotechnology sector with operations based in Heidelberg, Germany. The provided input does not include product-specific, technology-specific, or pipeline-specific details.
Is Glycotope Biotechnology a public or private company?
Glycotope Biotechnology is a private company. It is classified as unknown and is currently operating.
When was Glycotope Biotechnology founded?
Glycotope Biotechnology was founded in 2001. It employs 51 to 100 people.
Where is Glycotope Biotechnology based?
Glycotope Biotechnology is headquartered in Heidelberg, Germany, in the Europe region.
Who are Glycotope Biotechnology's main competitors?
Broad incumbents on record are Roche and Merck KGaA. AbCellera Biologics is listed as an emerging player. Evotec is listed as a regional player. Direct peers are MacroGenics, argenx, Genmab, BioInvent International and MorphoSys. Lonza Group is listed as an others.
Does Glycotope Biotechnology have an API?
No public API is recorded for Glycotope Biotechnology.
What industry is Glycotope Biotechnology in?
Glycotope Biotechnology's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325414 and its SIC code is 2836.